MedTrace Logo

A Study to Assess the Bioavailability of a New Tablet Formulation of Minzasolmin and the Effect of Food in Healthy Participants

NCT06533475 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-11-26

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to estimate the relative bioavailability of a new minzasolmin tablet formulation versus reference 'granules in capsule' formulation in healthy participants and to evaluate the effect of food with the new tablet formulation on the pharmacokinetics (PK) of minzasolmin.

Conditions

  • Healthy Participants

Interventions

DRUG

Minzasolmin tablet formulation under fasting condition

Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fasting condition

DRUG

Minzasolmin Granules in capsule under fasting condition

Drug: Minzasolmin Pharmaceutical form: Granules in capsule under fasting condition

DRUG

Minzasolmin tablet formulation under fed condition

Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fed condition

Sponsors & Collaborators

  • UCB Biopharma SRL

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-06
Primary Completion
2024-11-17
Completion
2024-11-17

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06533475 on ClinicalTrials.gov